Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:46:49 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:AMRN - AMARIN CORP SPON ADR EACH REP 20 ORD(P/S) - https://www.amarincorp.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AMRN - Q0.114.00·16.340.114.75+0.664.789.41,24597414.32  14.99  14.1420.90  7.0816:10:04Jan 0915 min RT 2¢

Recent Trades - Last 10 of 974
Time ETExPriceChangeVolume
16:10:04Q14.750.661
16:10:04Q14.750.661
16:04:12Q14.750.661
16:04:01Q14.750.661
16:00:03Q14.740.653
16:00:03Q14.750.6673
16:00:03Q14.750.662
16:00:03Q14.750.6628
16:00:03Q14.750.6610
16:00:03Q14.750.6628

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-09 07:00U:AMRNNews ReleaseAmarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA(TM)/VAZKEPA(TM) (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
2026-01-08 07:00U:AMRNNews ReleaseAmarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
2025-11-09 16:15U:AMRNNews ReleaseNew REDUCE-IT(TM) Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA(TM)/VAZKEPA(TM) (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
2025-11-03 08:30U:AMRNNews ReleaseAmarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
2025-10-29 07:00U:AMRNNews ReleaseAmarin Reports Third Quarter 2025 Financial Results
2025-10-27 08:00U:AMRNNews ReleaseAmarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
2025-10-15 08:00U:AMRNNews ReleaseAmarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
2025-10-14 08:00U:AMRNNews ReleaseAmarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT(TM) and EPA Mechanistic Data at the Canadian Cardiovascular Congress
2025-08-31 08:30U:AMRNNews ReleaseAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
2025-08-30 08:30U:AMRNNews ReleaseNew REDUCE-IT(TM) Analyses Presented at ESC 2025 Include Data Showing VASCEPA(TM)/VAZKEPA(TM) (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
2025-08-25 08:00U:AMRNNews ReleaseNew Analyses from REDUCE-IT(TM) and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
2025-07-30 07:00U:AMRNNews ReleaseAmarin Reports Second Quarter 2025 Financial Results
2025-07-23 07:30U:AMRNNews ReleaseAmarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
2025-06-24 07:00U:AMRNNews ReleaseAmarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA(TM) (Icosapent Ethyl) in Europe
2025-05-07 07:00U:AMRNNews ReleaseAmarin Reports First Quarter 2025 Financial Results
2025-04-29 16:15U:AMRNNews ReleaseAmarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
2025-04-28 16:15U:AMRNNews ReleaseAmarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
2025-04-09 07:30U:AMRNNews ReleaseAmarin Confirms Effective Date for 1-For-20 ADS Ratio Change
2025-04-07 07:30U:AMRNNews ReleaseAmarin Appoints JEC Capital Partners' Michael Torok to Board of Directors
2025-03-31 08:00U:AMRNNews ReleaseAmarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist